Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21


19304 items
9:31 AM, May 04, 2018  |  BioCentury | Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
5:05 AM, May 03, 2018  |  BioCentury | Finance

Foresite into data

With a new $668 million fund, Foresite Capital is positioning itself to invest in more healthcare companies that use data science and machine learning in drug discovery and development, diagnostics, and patient identification and monitoring....
3:02 AM, May 03, 2018  |  BioCentury | Finance

Rock the Casma

The recent discovery of autophagy-inducing targets led Third Rock Ventures to launch Casma Therapeutics Inc. with a $58.5 million series A to develop therapeutics that promote autophagy and ameliorate cellular distress in inflammatory, neurodegenerative, muscular...
5:46 PM, Apr 27, 2018  |  BioCentury | Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...
3:50 PM, Apr 27, 2018  |  BioCentury | Politics, Policy & Law

New hopes in IPR

The U.S. Supreme Court dashed biopharma’s hopes that the inter partes review system will quickly disappear, and threw a monkey wrench into the U.S. Patent and Trademark Office’s procedures for streamlining the adjudication of IPR...
2:48 PM, Apr 27, 2018  |  BioCentury | Regulation

Independent opportunities

The scenario the U.K. is trying to avoid is a full disconnect from EMA when the Brexit curtain falls. But a clean break from the agency could create opportunities for the U.K.’s Medicines and Healthcare...
1:43 PM, Apr 27, 2018  |  BioCentury | Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
1:32 PM, Apr 27, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 14 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Tel Aviv, before U.S. exchanges open CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgAllergan plc (NYSE:AGN)4/30Pre$3.35$3.350%Merck &...
8:05 AM, Apr 27, 2018  |  BioCentury | Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
5:04 AM, Apr 25, 2018  |  BioCentury | Finance

Rare disease rally

While 5AM Ventures has typically backed platform plays in the rare disease space, the firm is looking to newco Rallybio LLC to build a portfolio out of one-off rare disease candidates sourced from academia and...